Heart (British Cardiac Society) · 2026
Long-term cardiovascular outcomes in patients hospitalised with acute coronary syndrome subtypes in Western Australia, 2002-2019.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hung Joseph, Fudge Aaron, Lopez Derrick, Robinson Keira, Stacey Ingrid, Briffa Tom, Nedkoff Lee, Zemedikun Dawit
Аннотация
BACKGROUND: Despite advances in acute coronary syndrome (ACS) management, contemporary data assessing long-term prognosis after ST-segment elevation myocardial infarction (STEMI), non-STEMI (NSTEMI) and unstable angina (UA) are scarce.
METHODS: Linked hospitalisation and mortality data identified all 30-day survivors of index STEMI, NSTEMI and UA hospitalisation in Western Australia between 2002 and 2019. We assessed the cumulative 5-year incidence of major adverse cardiovascular events (MACE), comprising non-fatal MI, stroke, heart failure hospitalisation or cardiovascular death and separately all-cause death in 30-day survivors of index ACS hospitalisation. Associations were examined using Cox proportional hazards modelling after adjustment for potential confounders.
RESULTS: The cohort totalled 73 321 patients with ACS, 65% males, 22.3% with STEMI, 43.2% NSTEMI and 34.6% UA with mean age 63.2, 68.8 and 66.4 years, respectively. Patients with NSTEMI and UA compared with STEMI were more likely to be female with additional comorbidities. Cumulative 5-year MACE rates after NSTEMI were 29.7% vs 19.4% and 19.9% after STEMI and UA, respectively (log-rank p<0.001), while all-cause mortality was 29.8% vs 15.9% and 17.2%, respectively (log-rank p<0.001). There was no temporal improvement in multivariable-adjusted risk of outcomes for all ACS subtypes throughout the study period. The adjusted HRs for MACE and all-cause death were 1.5-fold or higher in males and females with STEMI or NSTEMI versus UA.
CONCLUSIONS: Long-term risk of MACE and all-cause death remains high and unchanged among 30-day survivors of all ACS subtypes in the recent era. Long-term surveillance and optimal secondary prevention are important in survivors of all ACS subtypes.
METHODS: Linked hospitalisation and mortality data identified all 30-day survivors of index STEMI, NSTEMI and UA hospitalisation in Western Australia between 2002 and 2019. We assessed the cumulative 5-year incidence of major adverse cardiovascular events (MACE), comprising non-fatal MI, stroke, heart failure hospitalisation or cardiovascular death and separately all-cause death in 30-day survivors of index ACS hospitalisation. Associations were examined using Cox proportional hazards modelling after adjustment for potential confounders.
RESULTS: The cohort totalled 73 321 patients with ACS, 65% males, 22.3% with STEMI, 43.2% NSTEMI and 34.6% UA with mean age 63.2, 68.8 and 66.4 years, respectively. Patients with NSTEMI and UA compared with STEMI were more likely to be female with additional comorbidities. Cumulative 5-year MACE rates after NSTEMI were 29.7% vs 19.4% and 19.9% after STEMI and UA, respectively (log-rank p<0.001), while all-cause mortality was 29.8% vs 15.9% and 17.2%, respectively (log-rank p<0.001). There was no temporal improvement in multivariable-adjusted risk of outcomes for all ACS subtypes throughout the study period. The adjusted HRs for MACE and all-cause death were 1.5-fold or higher in males and females with STEMI or NSTEMI versus UA.
CONCLUSIONS: Long-term risk of MACE and all-cause death remains high and unchanged among 30-day survivors of all ACS subtypes in the recent era. Long-term surveillance and optimal secondary prevention are important in survivors of all ACS subtypes.